{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:47:32Z","timestamp":1759366052331,"version":"build-2065373602"},"reference-count":3,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jaad.2019.08.088","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T21:30:21Z","timestamp":1569619821000},"page":"e31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rifampin and clindamycin are safe long-term: Response to \u201cNorth American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management\u201d"],"prefix":"10.1016","volume":"88","author":[{"given":"Joerg","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bigby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.08.088_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.08.088_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/bjd.17265","article-title":"Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A critically appraised topic","volume":"180","author":"Albrecht","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.08.088_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.17422","article-title":"Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa?","volume":"180","author":"Albrecht","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219327975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219327975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:05:00Z","timestamp":1759273500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219327975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":3,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0190962219327975"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.088","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rifampin and clindamycin are safe long-term: Response to \u201cNorth American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.02.067","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}